• Bellus Health Inc., of Laval, Quebec, and Thallion Pharmaceuticals Inc., of Dorval, Quebec, said Bellus agreed to acquire Thallion for about $6.3 million in cash, or about 17 cents per share (on a fully diluted basis), subject to certain adjustments, and the issuance of contingent value rights (CVRs).